Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HCA stock price vs AXP: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AXP's multiple
Needs AXP P/E.
Implied fair value · at HCA's multiple
Needs HCA P/E.
Price unavailable
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Higher is better
Asset efficiency edge
Lower is better
Statements
Reported bank earnings and balances, with each company’s reporting period shown.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity (USD)
—
Price / tangible book
—
Price / book
—
Net income / ending equity
—
Net income / ending assets
11.2%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity (USD)
—
Price / tangible book
—
Price / book
—
Net income / ending equity
32.4%
Net income / ending assets
3.6%
Efficiency ratio
128.7%
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Bear
$130.81
Base
$187.37
Bull
$261.03
AMERICAN EXPRESS CO · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
Visa Inc.
HCA vs V
Mastercard Incorporated
HCA vs MA
CAPITAL ONE FINANCIAL CORP
HCA vs COF
PayPal Holdings, Inc.
HCA vs PYPL
Synchrony Financial
HCA vs SYF
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA can maintain mid-single-digit-plus revenue growth without a further deterioration in margins, then HCA looks attractive relative to AXP because it trades at a much lower P/E and P/S while also showing stronger leverage metrics.
HCA trades at a meaningful valuation discount to AXP on both earnings and sales multiples. The current price of $410.50 sits below the DCF range and near the upper end of the historical band, while AXP-implied price suggests substantial upside if HCA were rerated toward AXP's multiple.
Supporting Metrics
